Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms

Hoi Ki Joshua Tam,Philip C. Robinson,Peter Nash
DOI: https://doi.org/10.1007/s11926-022-01084-4
2022-07-22
Current Rheumatology Reports
Abstract:Psoriatic arthritis and ankylosing spondylitis belong to a family of rheumatological diseases that lead to painful joint inflammation that impacts on patient function and quality of life. Recent studies have shown that the pro-inflammatory cytokine IL-17 is involved in the inflammatory joint changes in spondyloarthritides. We will review the pathophysiology of IL-17 and review the biological therapies targeting IL-17.
rheumatology
What problem does this paper attempt to address?